CSF Apo-E levels associate with cognitive decline and MRI changes
about
Cerebral atrophy in mild cognitive impairment: A systematic review with meta-analysisExpanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesIdentification of a Chrysanthemic Ester as an Apolipoprotein E Inducer in Astrocytes2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOEHDL-cholesterol and apolipoproteins in relation to dementia.Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease.The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.Relationship between APOE Genotype and Structural MRI Measures throughout Adulthood in the Study of Health in Pomerania Population-Based Cohort.Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's diseaseApolipoproteins and their subspecies in human cerebrospinal fluid and plasma.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update.Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease.A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.Entorhinal Cortex: Antemortem Cortical Thickness and Postmortem Neurofibrillary Tangles and Amyloid Pathology.The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma.
P2860
Q26744866-4E98FCE6-9C13-43EE-8EB6-C7679BA3CAFFQ26770708-8D098AC4-5C1C-4A1C-A2EC-5595B27E8676Q28553918-FD1E295F-A763-42FA-9DCD-AFC9EB2F0D46Q30971403-599BFDF8-6535-42B6-B0B6-25419D3BAF59Q35775365-8BE48B75-1B6E-4BE7-9AD3-343B2E9AB6C1Q36436743-556C88A2-3C6A-4707-BE0A-B2795E11593BQ36926775-7F55B0B3-55BB-45F3-BC48-62F2C65F82DBQ37451440-B7CB4695-F120-426B-89B9-AFC9AEF51F9FQ37500400-79B02556-2C36-46F0-8B72-4BE89AFB848EQ37557940-51E241D0-7AED-42EE-8887-C1DFF91BFB60Q37682703-C64C501F-A65D-4FC9-9C64-3D29F48DF96FQ38289739-B885227F-9018-4E1B-B56C-83ADAC897BCAQ38959290-08E8973E-8A9E-4DA4-B309-6DCB790A90ABQ39257249-F8CC5490-4A6E-4DDF-8CB5-762F669196AFQ40101067-05416505-E978-44BC-AF6B-048BA8ACE4C9Q42619991-01B74AC1-A740-4858-BC57-06AE0A0F2DF4Q47568641-9AB1DA64-B9A2-4FED-AE1F-0DBFAAC2F322Q47599699-B2C7B47F-D724-4059-88FC-6DA00EAA2DDC
P2860
CSF Apo-E levels associate with cognitive decline and MRI changes
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CSF Apo-E levels associate with cognitive decline and MRI changes
@en
CSF Apo-E levels associate with cognitive decline and MRI changes.
@nl
type
label
CSF Apo-E levels associate with cognitive decline and MRI changes
@en
CSF Apo-E levels associate with cognitive decline and MRI changes.
@nl
prefLabel
CSF Apo-E levels associate with cognitive decline and MRI changes
@en
CSF Apo-E levels associate with cognitive decline and MRI changes.
@nl
P2093
P2860
P50
P1476
CSF Apo-E levels associate with cognitive decline and MRI changes
@en
P2093
David A Wolk
Leslie M Shaw
Sharon X Xie
P2860
P2888
P304
P356
10.1007/S00401-013-1236-0
P50
P577
2014-01-03T00:00:00Z